Context Therapeutics is trading 25% down at $0.52 after reporting a $14.6 million second-quarter net loss and missing consensus EPS estimates by $0.05.
- Discontinued CT-95 development to prioritize CTIM-76 and CT-202.
- Research and development expenses increased to $12.5 million.
- Cash totaled $43.0 million, expected to fund operations into the fourth quarter of 2027.